EFFECT OF DRUG METABOLISING ENZYME CYTOCHROME CYP2C9 GENE POLYMORPHISM ON TREATMENT RESPONSE IN CARCINOMA OF OROPHARYNX AND HYPOPHARYNX

Siddararth Kumar; Sudhir Singh; Abhishek Dubey; Kirti Srivastava; Disha Tiwari; Rajeev Gupta

Volume : VIII, Issue : II, February - 2018

EFFECT OF DRUG METABOLISING ENZYME CYTOCHROME CYP2C9 GENE POLYMORPHISM ON TREATMENT RESPONSE IN CARCINOMA OF OROPHARYNX AND HYPOPHARYNX

Siddararth Kumar, Sudhir Singh, Abhishek Dubey, Kirti Srivastava, Disha Tiwari, Rajeev Gupta

Abstract :

This study was carried out to investigate the association of polymorphism in cytochrome P450 2C9 (CYP2C9) with response in patients receiving chemoradiotherapy. One hundred males suffering from locally advanced squamous cell carcinoma were genotyped for CYP2C9*2 and CYP2C9*3, leading to poor metabolizers (PMs)by PCR–based RFLP. Each case was assessed thoroughly for treatment response following WHO criteria. Cases assessed for response carrying variant alleles of both CYP2C9*2 (46.0%) or CYP2C9*3 (22.0%) were found to respond poorly to the radio–chemotherapy. The data suggests a significant association SCC of oropharynx and hypopharynxand treatment outcome with the CYP2C9 polymorphism and underlining the importance of pre–therapeutic genotyping in determining the treatment modality. < clear="all" style="page–eak–before:always; mso–eak–type:section–eak" />